On the Blog: Reforming clinical trials will take shared leadership.
 â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â
Problems viewing this email?
View Message In Browser
The Latest Research, Commentary, And News From Health Affairs
Wednesday, August 25, 2021
Dear John,
Three papers in the August 2021 issue of Health Affairs discuss
pharmaceutical research.
Biosimilars & Drug Development
**** Research featured in the August issue explores biosimilars,
pharmaceutical competition, and review vouchers.
Victor Van de Wiele and colleagues examine patent litigation related to
biosimilars
.
They identify two key barriers to a robust market in the US:
noncompliance in the litigation process and extensive patenting of
biologic drugs by originator manufacturers.
James Robinson and Quentin Jarrion study biosimilars in France
,
analyzing national tariff prices from 2004 to 2019 for three prominent
drugs and eleven competing biosimilars. "The French market exhibits
robust competition among biosimilars as well as between biosimilars and
their reference biologics," they conclude.
David Ridley and coauthors provide case studies for Tropical Disease
Priority Review Vouchers
awarded between 2007 and 2018. They find that the returns from a voucher
neither drive end-to-end drug development nor fund and deliver access.
Today on Health Affairs Blog, Katie Keith discusses the new frequently
asked questions
issued by the Departments of Labor, Health and Human Services, and the
Treasury on the implementation of various transparency requirements
under the Consolidated Appropriations Act.
Esther Krofah and coauthors discuss why the shared leadership to reform
our clinical trials enterprise
must include a variety of stakeholders, including groups dedicated to
reducing disparities and increasing access to care.
Check out our COVID-19 Resource Center
for Health
Affairs content about all things related to the pandemic.
Your Daily Digest
Barriers To US Biosimilar Market Growth: Lessons From Biosimilar Patent
Litigation
Victor L. Van de Wiele et al.
Competition From Biosimilars Drives Price Reductions For Biologics In
The French Single-Payer Health System
James C. Robinson and Quentin Jarrion
US Tropical Disease Priority Review Vouchers: Lessons In Promoting Drug
Development And Access
David B. Ridley et al.
New Guidance On Transparency Requirements, Advanced Explanations Of
Benefits, And More
Katie Keith
Clinical Trials In Crisis: Building On COVID-19's Lessons Toward A
Better Future
Esther Krofah et al.
Â
[link removed]
[link removed]
Â
[link removed]
Â
[link removed]
Â
[link removed]
Â
mailto:
[email protected]
About Health Affairs
Health Affairs is the leading peer-reviewed journal
at the intersection of health,
health care, and policy. Published monthly by Project HOPE, the journal
is available in print and online. Late-breaking content is also found
through healthaffairs.org , Health
Affairs Today , and Health
Affairs Sunday Update . Â
Project HOPE is a global health and
humanitarian relief organization that places power in the hands of local
health care workers to save lives across the globe. Project HOPE has
published Health Affairs since 1981.
Copyright © Project HOPE: The People-to-People Health Foundation, Inc.
Health Affairs, 7500 Old Georgetown Road, Suite 600, Bethesda, MD 20814, United States
Privacy Policy
To unsubscribe from this email, click here
.
_________________
Sent to
[email protected]
Unsubscribe:
[link removed]
Health Affairs, 7500 Old Georgetown Road, Suite 600, Bethesda, MD 20814, United States
